Weight Loss Peptide
Synthetic peptide commonly studied for its role in cellular repair mechanisms involving connective tissue, muscle, tendon, and gastrointestinal systems.
Weight Loss Peptide
GLP-1 T
Synthetic peptide commonly studied for its role in cellular repair mechanisms involving connective tissue, muscle, tendon, and gastrointestinal systems.
1
$79.99
Most Popular
Best Value
Est. delivery Apr 10 - Apr 14
Free shipment protection
Secure checkout
We accept:
Free shipping
on orders over $200
Damage protection
on every order
Secure checkout
256-bit SSL
Certificate of Analysis
Tested for Identification, Purity, Mass, Endotoxins, Sterility, and Heavy Metals
LATEST
SELECTED DOSAGE
99.47%
PURITY
Variant
GLP-1 T 10MG
Lot #
TRZ-2601-A01
Labeled
10mg
Actual
10.83mg
Tested
March 07, 2026
LATEST
99.33%
PURITY
Variant
GLP-1 T 20MG
Lot #
TRZ-2601-A02
Labeled
20mg
Actual
21.25mg
Tested
March 06, 2026
LATEST
99.71%
PURITY
Variant
GLP-1 T 30MG
Lot #
TRZ-2601-B01
Labeled
30mg
Actual
32.64mg
Tested
March 07, 2026
LATEST
99.58%
PURITY
Variant
GLP-1 T 60MG
Lot #
TRZ-2601-B01
Labeled
60mg
Actual
61.75mg
Tested
March 07, 2026
LATEST
99.29%
PURITY
Variant
GLP-1 T 100MG
Lot #
TRZ-2601-B03
Labeled
100mg
Actual
103.98mg
Tested
March 07, 2026
LATEST
99.44%
PURITY
Variant
GLP-1 T 120MG
Lot #
TRZ-2601-B04
Labeled
120mg
Actual
123.72mg
Tested
March 07, 2026
Compound Information
Pharmaceutical Specifications
Molecular Profile
What Is GLP-1 T?
TypeSynthetic peptide
CAS Number2023788-19-2
Molecular FormulaC₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight4,813.47 g/mol
Amino Acids39
Storage Requirements
Stability Information
Lyophilized (powder)
-20°C · 24+ months
Reconstituted
2-8°C · ~30 days
Research
Sources & References
NEW ENGLAND JOURNAL OF MEDICINE
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
View Source
NEW ENGLAND JOURNAL OF MEDICINE
Tirzepatide for Obesity Treatment and Diabetes Prevention — 3-Year SURMOUNT-1 Extension
View Source
NEW ENGLAND JOURNAL OF MEDICINE
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)
View Source
NEW ENGLAND JOURNAL OF MEDICINE
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT Trial)
View Source
NEW ENGLAND JOURNAL OF MEDICINE
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)
View Source
NEW ENGLAND JOURNAL OF MEDICINE
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT)
View Source
THE LANCET
Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1)
View Source
NEW ENGLAND JOURNAL OF MEDICINE
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
View Source
NATURE MEDICINE
Tirzepatide Cardiovascular Event Risk Assessment: A Pre-Specified Meta-Analysis
View Source
CIRCULATION (AHA)
Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, Preserved Ejection Fraction, and Obesity (SUMMIT)
View Source
Additional information
Quantity:
10MG, 10MG (Three Vials), 20MG, 20MG (Three Vials), 30MG, 30MG (Three Vials), 60MG, 60MG (Three Vials), 100MG, 100MG (Three Vials), 120MG, 120MG (Three Vials)
